Table 2.
Surgical procedure and chemotherapy of patients with and without tumor recurrence
| Procedure and chemotherapy | Recurrence (n=128) | Nonrecurrence (n=119) | P-value |
|---|---|---|---|
| Surgical procedures | |||
| Lobectomy | 115 (89.8) | 101 (84.9) | 0.403 |
| Bilobectomy (RUL and RML) | 4 (3.1) | 3 (2.5) | |
| Bilobectomy (RLL and RML) | 8 (6.3) | 11(9.2) | |
| Pneumonectomy | 1 (0.8) | 4 (3.4) | |
| Chemotherapy | |||
| No chemotherapy | 60 (46.9) | 71 (59.7) | 0.129 |
| Adjuvant chemotherapy | 60 (46.9) | 43 (36.1) | |
| Neoadjuvant chemotherapy | 8 (6.3) | 5 (4.2) | |
| Chemotherapy regimens | |||
| Paclitaxel plus platinum | 31 (47.0) | 27 (56.3) | 0.914 |
| Docetaxel plus platinum | 10 (15.2) | 5 (10.4) | |
| Navelbine plus platinum | 11 (16.7) | 7 (14.6) | |
| Gemcitabine plus platinum | 3 (4.6) | 2 (4.2) | |
| Other platinum-based regimens | 11 (16.7) | 7 (14.6) | |
Note: Values are n (%).
Abbreviatons: n, number; RUL, right upper lobe; RML, right middle lobe.